January 2023 in “Revista Brasileira de Parasitologia Veterinária/Brazilian Journal of Veterinary Parasitology” A single dose of fluralaner effectively treats mite infestations in cats without side effects.
March 2002 in “Hair transplant forum international” Dutasteride's effect on hair loss treatment is uncertain and should be used cautiously.
July 2013 in “Edinburgh Research Archive (University of Edinburgh)” Dutasteride may reduce insulin sensitivity and increase body fat.
January 2025 in “JAAD International” Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
November 2023 in “PubMed” Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
38 citations
,
January 2005 in “PubMed” Dutasteride effectively treats enlarged prostate with manageable side effects.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
1 citations
,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
5 citations
,
December 1979 in “Clinical and Experimental Dermatology” Anti-androgens are effective for female acne but less so for male-pattern hair loss, with side effects similar to birth control pills.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
September 2024 in “Dermatology” Dutasteride works better than finasteride for hair loss and has mild, reversible side effects.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
April 2023 in “Journal of Investigative Dermatology” A new treatment for hair loss shows promise with fewer side effects.
January 2008 in “Annals of Nutrition and Metabolism” Parthenolide promotes hair growth in mice and may influence pathways related to male pattern baldness.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
August 2020 in “European Journal of Dermatology” Dutasteride for hair loss can cause skin reactions like itchy red plaques.
45 citations
,
January 2008 in “Drugs” Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
27 citations
,
January 2001 in “Hormone Research in Paediatrics” Low-dose flutamide effectively maintains reduced hirsutism with no side effects.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
13 citations
,
December 2012 in “Canadian Urological Association Journal” 5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
14 citations
,
May 2008 in “Journal of proteome research” Dutasteride may help reduce brain plaque linked to Alzheimer's by affecting cell energy structures and waste removal.
January 2008 in “프로그램북(구 초록집)”
75 citations
,
October 1999 in “European journal of endocrinology” Finasteride is a safe, effective treatment for hirsutism with fewer side effects.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.